ERBB2 and non-small cell lung carcinoma: In NSCLC, poziotinib, a TKI, had demonstrated activity in 12 heavily pre-treated patients with HER2 exon-20 insertion, as it was T-DM1 (ORR of 42% and 38.1%, respectively) [46,47].